ReviewOncogene2024
MicroRNAs: circulating biomarkers for the early detection of imperceptible cancers via biosensor and machine-learning advances.
Review in Oncogene, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 102 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
102 citing papers in PubMed, 6 syntheses or guidelines pooled it.
- Circulating microRNAs: a new era in early detection of oral squamous cell carcinoma (OSCC) - a systematic review and meta-analysis.Journal of the Egyptian National Cancer Institute · 2026Pooled it
- Can MicroRNAs serve as reliable biomarkers and novel therapeutic targets in age-related macular degeneration? A systematic review and meta-analysis.Journal of translational medicine · 2026Pooled it
- Diagnostic Potential of Circulating miRNAs in Glioma: A Systematic Review and Meta-Analysis.International journal of molecular sciences · 2026Pooled it
- The research progress on diagnostic indicators related to prostate-specific antigen gray-zone prostate cancer.BMC cancer · 2025Pooled it
- Pooled it
- Circulating miRNAs as liquid biopsy biomarkers for diagnosis in patients with colorectal cancer: a systematic review and meta-analysis.Frontiers in genetics · 2025Pooled it
- Circulating MicroRNAs in non-small cell lung cancer: Clinical potential, analytic pitfalls, and barriers to implementation.The journal of liquid biopsy · 2026Review
- Multi-Institutional Integration of Circulating miRNAs and Protein Tumor Markers for Early Lung Cancer Detection.JTO clinical and research reports · 2026Article
- Identification of a circulating miR-6838-5p/miR-195-5p signature in invasive ductal breast carcinoma.Molecular biology reports · 2026Article
- Article
- Polyaniline-gold nanoparticle-based biosensor targeting miR-21-5p for early diagnosis of leptospirosis.Analytical and bioanalytical chemistry · 2026Article
- Role of liquid biopsy in the multimodal assessment and treatment of esophageal cancer: a surgical perspective.Updates in surgery · 2026Article
- Estradiol Ameliorates Postmenopausal Bladder Dysfunction by Restoring Mitophagy via the miRNA-200/KLF4/mTOR Signaling Pathway.International journal of molecular sciences · 2026Article
- Evaluating the influence of different anticoagulant blood collection tubes on the efficiency of circulating RNA extraction and Real-Time PCR quantification.Molecular biology reports · 2026Article
- Orthogonal DNA barcoding enables subpopulation-resolved extracellular vesicle miRNA profiling.Science advances · 2026Article
- Article
- Amplification-Free Detection of MiRNA Signatures in Milk: A Noninvasive Sensing Approach for Early Diagnosis of Bovine Mastitis.ACS measurement science au · 2026Article
- DNA-Based Boolean Logic Gates for Molecular Computation and Biosensing: A Critical Review.Molecular biotechnology · 2026Review
- PANDORA-seq reveals human sperm sncRNA signature endowed with sperm quality assessment.Genes & diseases · 2026Article
- SAFE: a Mix-and-Read Assay for miRNA Detection in Extracellular Vesicles From Unprocessed Plasma Toward Clinical Disease Diagnosis.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
42 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This review explores the topic of microRNAs (miRNAs) for improved early detection of imperceptible cancers, with potential to advance precision medicine and improve patient outcomes. Historical research exploring miRNA's role in cancer detection collectively revealed initial hurdles in identifying specific miRNA signatures for early-stage and difficult-to-detect cancers. Early studies faced challenges in establishing robust biomarker panels and overcoming the heterogeneity of cancer types. Despite this, recent developments have supported the potential of miRNAs as sensitive and specific biomarkers for early cancer detection as well as having demonstrated remarkable potential as diagnostic tools for imperceptible cancers, such as those with elusive symptoms or challenging diagnostic criteria. This review discusses the advent of high-throughput technologies that have enabled comprehensive detection and profiling of unique miRNA signatures associated with early-stage cancers. Furthermore, advancements in bioinformatics and machine-learning techniques are considered, exploring the integration of multi-omics data which have potential to enhance both the accuracy and reliability of miRNA-based cancer detection assays. Finally, perspectives on the continuing development on technologies as well as discussion around challenges that remain, such as the need for standardised protocols and addressing the complex interplay of miRNAs in cancer biology are conferred.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.